Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended 2-year follow-up of short-term intensive insulin followed by exenatide in newly diagnosed type 2 diabetes
ChiCTR-IPR-15006298Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2013
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of exenatide, human insulin, metformin and gliclazide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Remission rate. Started Jun 2013; status: recruiting.
02
Drugs
exenatidehuman insulinmetformingliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-15006298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006298.